1. March of Dimes Foundation: March of Dimes White paper on preterm birth:
the global and regional toll. White Plains, New York: March of Dimes
foundation; 2009.
2. Norman JE, Morris C, Chalmers J: The effect of changing patterns of
obstetric care in Scotland (1980–2004) on rates of preterm birth and its
neonatal consequences: perinatal database study. PLoS Med 2009,
6(9):e1000153.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R: Epidemiology and causes
of preterm birth. Lancet 2008, 371(9606):75–84.
4. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P,
Prendiville W, Paraskevaidis E: Perinatal mortality and other severe
adverse pregnancy outcomes associated with treatment of cervical
intraepithelial neoplasia: meta-analysis. BMJ (Clinical Res Ed) 2008,
337:a1284.
5. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M: Prophylactic
administration of progesterone by vaginal suppository to reduce the
incidence of spontaneous preterm birth in women at increased risk: a
randomized placebo-controlled double-blind study. Am J ObstetGynecol
2003, 188(2):419–424.
6. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Thornton S, Alfirevic Z,
Smith G, Radhakrishnan P, Khoury O, et al: Progesterone and the risk of
preterm birth among women with a short cervix. N Engl J Med 2007,
357(5):462–469.
7. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong
CY, Hauth JC, Miodovnik M, Varner MW, et al: Prevention of recurrent
preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J
Med 2003, 348(24):2379–2385.
8. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter J, Khandelwal M,
Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, et al: Vaginal
progesterone reduces the rate of preterm birth in women
with a sonographic short cervix: a multicenter, randomized,
double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011,
38:18–31.
9. Dodd JM, Flenady V, Cincotta R, Crowther CA: Prenatal administration of
progesterone for preventing preterm birth. Cochrane Database Syst Rev
2006, 1:CD004947.
10. Dodd JM, Flenady VJ, Cincotta R, Crowther CA: Progesterone for the
prevention of preterm birth: a systematic review. Obstet Gynecol 2008,
112(1):127–134.
11. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O'Brien JM, Cetingoz E,
Da Fonseca E, Creasy GW, Klein K, Rode L, et al: Vaginal progesterone
in women with an asymptomatic sonographic short cervix in the
midtrimester decreases preterm delivery and neonatal morbidity:
a systematic review and metaanalysis of individual patient data.
Am J Obstet Gynecol 2012, 206(2):124 e121–119.
12. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M,
Swain M, Bousleiman S, Johnson F, Dorman K, et al: Follow-up of children
exposed in utero to 17 alpha-hydroxyprogesteronecaproate compared
with placebo. ObstetGynecol 2007, 110(4):865–872.
13. Progesterone and preterm birth prevention: translating clinical trials
data into clinical practice. Am J Obstet Gynecol 2012, 206(5):376–386.
14. Junpeng M, Huang S, Qin S: Progesterone for acute traumatic brain
injury. Cochrane Database Syst Rev 2011, 1:CD008409.
15. Kenyon SL, Taylor DJ, Tarnow-Mordi W: Broad-spectrum antibiotics for
spontaneous preterm labour: the ORACLE II randomised trial. ORACLE
Collaborative Group. Lancet 2001, 357(9261):989–994.
16. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, Taylor DJ:
Childhood outcomes after prescription of antibiotics to pregnant
women with spontaneous preterm labour: 7-year follow-up of the
ORACLE II trial. Lancet 2008, 372(9646):1319–1327.
17. Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, Colton T,
Hartge P, Hatch EE, Herbst AL, et al: Adverse health outcomes in women
exposed in utero to diethylstilbestrol. N Engl J Med 2011,
365(14):1304–1314.
18. Anon: Disability and Perinatal care: report of two working groups. Oxford:
NEPU and Oxford HA; 1995.
19. Modi N, Dore CJ, Saraswatula A, Richards M, Bamford KB, Coello R,
Holmes A: A case definition for national and international neonatal
bloodstream infection surveillance. Arch Dis Child 2009,
94(1):F8–F12.
20. Standards for hospitals providing neonatal intensive and high dependency care
and categories of babies requiring neonatal care. 2nd edition.: British
Association of Perinatal Medicine; 2001. http://www.bapm.org/publications/
documents/guidelines/hosp_standards.pdf.
21. BAPM/RCPCH Working Group Report: Classification of health status at 2 years
as a perinatal outcome. 2008.
22. Edwards IR, Biriell C: Harmonisation in pharmacovigilance. Drug Saf 1994,
10(2):93–102.
23. Honest H, Forbes CA, Duree KH, Norman G, Duffy SB, Tsourapas A, Roberts
TE, Barton PM, Jowett SM, Hyde CJ, et al: Screening to prevent
spontaneous preterm birth: systematic reviews of accuracy and
effectiveness literature with economic modelling. Health Technol Assess
2009, 13(43):1–627.
24. Lachenbruch PA: Analysis of data with excess zeros. Stat Methods Med Res
2002, 11(4):297–302.
25. Farine D, Mundle WR, Dodd J, Basso M, Delisle MF, Grabowska K, Hudon L,
Menticoglou SM, Murphy-Kaulbeck LC, Ouellet A, et al: The use of
progesterone for prevention of preterm birth. J Obstet Gynaecol Can 2008,
30(1):67–77.
26. American College of Obstetricians and Gynecologists: ACOG committee
opinion no 419.on "The use of progesterone to prevent preterm birth".
American College of Obstetricians and Gynecologists. Obstet Gynecol
2008, 112:963–965.
27. Shennan A, Jones G, Hawken J, Crawshaw S, Judah J, Senior V, Marteau T,
Chinn S, Poston L: Fetal fibronectin test predicts delivery before
30 weeks of gestation in high risk women, but increases anxiety. BJOG
2005, 112(3):293–298.
28. Sanchez-Ramos L, Kaunitz AM, Delke I: Progestational agents to prevent
preterm birth: a meta-analysis of randomized controlled trials. Obstet
Gynecol 2005, 105(2):273–279.
29. Wolke D, Meyer R: Ergebnisse der Bayerischen Entwicklungstudie:
implikationen fur theorie und praxis. Kindheit und Entwicklung 1999,
8:24–36.